Session » Pediatric Rheumatology - Clinical and Therapeutic Aspects Posters (ACR): Imaging and Novel Clinical Interventions

Date: Tuesday, November 10, 2015

Time: 9:00AM-11:00AM

Meeting: 2015 ACR/ARHP Annual Meeting

9:00AM-11:00AM: Abstract Number: 2444

Accelerometer-Assessed Daily Physical Activity in Relation to Pain Cognitions and Quality of Life in Juvenile Idiopathic Arthritis

9:00AM-11:00AM: Abstract Number: 2423

An Open-Label Extension Study to Assess the Long-Term Safety and Clinical Benefit of Etanercept on Children and Adolescents with Extended Oligoarticular Juvenile Idiopathic Arthritis, Enthesitis-Related Arthritis, or Psoriatic Arthritis: A 4-Year Update

9:00AM-11:00AM: Abstract Number: 2433

Anti Interferon-Gamma (IFNg) Monoclonal Antibody Treatment in a Child with NLRC4-Related Disease and Severe Hemophagocytic Lymphohistiocytosis (HLH)

9:00AM-11:00AM: Abstract Number: 2420

Azathioprine for Glucocorticoid Resistant Non-Renal Henoch-Schönlein Purpura

9:00AM-11:00AM: Abstract Number: 2452

Clinical and Functional Outcomes in Patients with Polyarticular Juvenile Idiopathic Arthritis Following Treatment with Adalimumab

9:00AM-11:00AM: Abstract Number: 2438

Clinical Examination of the Temporomandibular Joint; A Eurotmjoint Initiative

9:00AM-11:00AM: Abstract Number: 2445

Development and Usability Testing of an Ipad-Based Psycho-Educational Game for Children with Juvenile Idiopathic Arthritis and Their Parents

9:00AM-11:00AM: Abstract Number: 2449

Does Antinuclear Antibodies Predict Remission in JIA ?

9:00AM-11:00AM: Abstract Number: 2428

Efficacy and Safety of Adalimumab in Adult Patients with Polyarticular Juvenille Idiopathic Arthritis

9:00AM-11:00AM: Abstract Number: 2422

Efficacy and Safety of Canakinumab in Children with Systemic Juvenile Idiopathic Arthritis: Results from the Phase 3 Extension Study

9:00AM-11:00AM: Abstract Number: 2453

Evidence-Based Decision Support for Pediatric Rheumatology Reduces Diagnostic Errors, with the Potential to Reduce Capacity Shortage

9:00AM-11:00AM: Abstract Number: 2450

Examination of the Clinical Significance of 14-3-3 Eta in Juvenile Idiopathic Arthritis

9:00AM-11:00AM: Abstract Number: 2421

Experience with Adalimumab for Treatment of 568 Juvenile Idiopathic Arthritis Patients in the German JIA Biologics Register

9:00AM-11:00AM: Abstract Number: 2437

Experience with Tocilizumab for Treatment of 56 Children with Systemic Juvenile Idiopathic Arthritis in the German JIA Biologics Register

9:00AM-11:00AM: Abstract Number: 2448

Flare Definitions for Juvenile Idiopathic Arthritis (JIA) Based on ACR Core Set Variables and Patient Reported Outcomes: Results from the Research in Arthritis in Canadian Children-Emphasizing Outcomes Prospective Cohort

9:00AM-11:00AM: Abstract Number: 2430

Immunological Risk Factors after Rituximab Therapy in Patients with Pediatric Rheumatic Diseases – a Prospective Single-Center Study

9:00AM-11:00AM: Abstract Number: 2417

Induction and Maintenance of Remission By Etanercept in Enthesitis Related Arthritis JIA-Patients

9:00AM-11:00AM: Abstract Number: 2427

Long-Term Efficacy and Safety of Mycophenolate Mofetil in Childhood Primary Central Nervous System Vasculitis

9:00AM-11:00AM: Abstract Number: 2431

Long-Term Safety of Adalimumab Treatment in Pediatric Patients with Polyarticular Juvenile Idiopathic Arthritis and Enthesitis-Related Arthritis

9:00AM-11:00AM: Abstract Number: 2424

Macrophage Activation Syndrome in Systemic Juvenile Idiopathic Arthritis Patients Treated with Canakinumab: Results from Phase 3 Trial Program

9:00AM-11:00AM: Abstract Number: 2426

Medication Taper and Risk of Relapse in Pediatric Uveitis

9:00AM-11:00AM: Abstract Number: 2439

Methotrexate Failure in Pediatric Uveitis

9:00AM-11:00AM: Abstract Number: 2418

Pediatric Enthesitis-Related Arthritis: Variation in Disease Characteristics and Treatments Among 5 Large Centers

9:00AM-11:00AM: Abstract Number: 2443

Pediatric Tele-Rheumatology: A Pilot Project to Assess Accuracy of Physical Examination Findings and Diagnostic Concordance at a Distance

9:00AM-11:00AM: Abstract Number: 2416

Pharmacokinetics, Safety, and Tolerability of Tofacitinib in Pediatric Patients from Six to Less Than Eighteen Years of Age with Juvenile Idiopathic Arthritis

9:00AM-11:00AM: Abstract Number: 2435

Pregnancy Outcomes in Adult Juvenile Idiopathic Arthritis Patients Treated with Biologic Agents

9:00AM-11:00AM: Abstract Number: 2434

Promis Tools for Measurement of Patient-Reported Outcomes in Children with Juvenile Arthritis

9:00AM-11:00AM: Abstract Number: 2419

Safety and Efficacy of Etanercept in 2000 Patients with Juvenile Idiopathic Arthritis (JIA) in the JIA Biologics Register

9:00AM-11:00AM: Abstract Number: 2425

Safety of Tocilizumab in Young Adults with Juvenile Idiopathic Arthritis (JIA)

9:00AM-11:00AM: Abstract Number: 2451

Scoring Medication Requirements and Side-Effects in Juvenile Idiopathic Arthritis: Perspectives of Patients, Parents and Clinicians

9:00AM-11:00AM: Abstract Number: 2441

Serum 14-3-3η Is Present in JIA and Is Not Associated with RF+ Polyarthritis

9:00AM-11:00AM: Abstract Number: 2446

Synovial Fluid Proteins Differentiate Patients with Oligoarticular Juvenile Idiopathic Arthritis Who Are Destined to Extend from Those Who Will Remain Persistent in Course

9:00AM-11:00AM: Abstract Number: 2442

The Family Journey to Diagnosis with Systemic Juvenile Idiopathic Arthritis As Evidenced through Changing Social Media Presence

9:00AM-11:00AM: Abstract Number: 2447

The Juvenile Arthritis Disease Activity Score Remains the Disease Activity Marker of Choice for Adults with Polyarticular Juvenile Idiopathic Arthritis

9:00AM-11:00AM: Abstract Number: 2432

The Preventive Effect of Methotrexate on Uveitis Onset in JIA Depends on Uveitis Risk Factors

9:00AM-11:00AM: Abstract Number: 2415

Use of Plasma Exchange for Children Hospitalized with ANCA-Associated Vasculitis in the United States

9:00AM-11:00AM: Abstract Number: 2440

Using Patient-Relevant Variables to Describe the Disease Course in Children with Juvenile Idiopathic Arthritis

9:00AM-11:00AM: Abstract Number: 2429

Varicella Vaccination in Patients with Pediatric Rheumatic Diseases Receiving Immunosuppression: Proposal of a Pre-Vaccination Checklist to Ensure Safety

9:00AM-11:00AM: Abstract Number: 2436

Views and Prescribing Habits of Pneumocystis Prophylaxis in the Pediatric Rheumatology Community

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].